Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Suits And Letters, In Brief

Executive Summary

Schering's Pegintron gets complete response letter: FDA handed Schering-Plough a complete response letter for Pegintron (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy. In early October, FDA's Oncologic Drugs Advisory Committee recommended approval of the biologic by a vote of 6 to 4, despite FDA's concern about modest improvement in relapse-free survival and no benefit in overall survival. The agency said the latter point was especially relevant given that the current standard of care - Schering's own Intron A - did show an improvement in overall survival during the clinical trials that supported its 1995 approval. Schering would not comment on any new trials or data FDA requested in the letter. Pegintron is currently approved in the U.S. for use in combination with Rebetol (ribavirin) for the treatment of chronic hepatitis C in patients three years of age and older with compensated liver disease (1"The Pink Sheet" DAILY, Oct. 5, 2009)

You may also be interested in...



Despite FDA Reservations, ODAC Votes Yes On Schering's PegIntron And GSK's Votrient

The panel voted 6-4 to recommend approval of the sBLA for PegIntron (peginterferon alfa-2b) for melanoma, and unanimously for Glaxo's Votrient (pazopanib) for advanced renal cell carcinoma.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Topics

UsernamePublicRestriction

Register

PS051636

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel